Effect of Hypothyroidism on Brown Adipose Tissue

University Hospital Basel

Status: Completed

Conditions: Hypothyroidism

Study type: Observational

Funder types: Other

Identifiers

NCT02364102

EKNZ 2015-028

Details and patient eligibility

About

The investigators aim to study whether hypothyroidism negatively affects Brown adipose tissue (BAT) function in humans and whether BAT function can be restored to normal by thyroid hormone supplementation.

Full description

Hypothyroidism is a frequent endocrine disorder, the prevalence of subclinical disease being 4.3% and of overt disease being 0.3%. Patients suffering from hypothyroidism frequently complain of increased cold sensitivity and involuntary weight gain, indicating changes in energy expenditure and response to cold challenge.

Recently, brown adipose tissue (BAT) has regained attention as an energy expending tissue. While it was previously thought to be of no or negligible relevance in human adults, recent studies clearly demonstrated the presence and metabolic activity of BAT in human adults. Upon activation of BAT by the sympathetic nervous system intracellular lipid stores are rapidly depleted. The generated free fatty acids fuel beta-oxidation and the respiratory chain within the mitochondria and activate at the same time uncoupling protein 1 (UCP1). This protein acts as a protonophore, allowing the flux of protons along the electrochemical gradient into the inner mitochondrial matrix instead of transferring their energy to adenosine triphosphate (ATP)-synthase. The short circuiting of the oxidative phosphorylation within the mitochondria leads to highly active cellular respiration and generation of heat. Basic research highlights the importance of thyroid hormone in the development and function of BAT.

It has recently been shown that hyperthyroidism exerts activating effects on BAT in adult humans.

The investigators aim to study whether hypothyroidism negatively affects BAT function in humans and whether BAT function can be restored to normal by thyroid hormone supplementation.

Enrollment: 42 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• informed consent
• Serum thyroid-stimulating hormone (TSH) > 4.5 milli-International unit (mIU)/l
• body mass index (weight/height(m)²) 17.5 to 30 kg/m²

Exclusion criteria

• known concomitant disease influencing thyroid hormone metabolism
• chronic heart failure
• liver cirrhosis
• severe kidney failure
• metastasized cancer, except for thyroid cancer
• known hypersensitivity to cold, e.g. primary or secondary Raynaud's syndrome
• abuse of alcohol or illicit drugs
• Women who are pregnant or breast feeding
• Intention to become pregnant during the course of the study
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
• Participation in another study with investigational drug within the 30 days preceding and during the present study
• Previous enrolment into the current study